HLS Healius Ltd
- 1.150
- +0.050+4.55%
Healius Ltd News
Healius May Not Get the Strong 4Q It Needs -- Market Talk
2140 GMT - Pathology services provider Healius is banking on a strong 4Q to achieve its earnings guidance, but Jefferies is skeptical it can get there. In a note, analyst David Stanton says Healius's
Healius Price Target Cut 1.7% to A$1.18/Share by Jefferies
Healius Price Target Cut 1.7% to A$1.18/Share by Jefferies
Morgan Stanley Adjusts Healius' Price Target to AU$1 From AU$1.30, Keeps at Underweight
Healius (ASX:HLS) has an average rating of underperform and price targets ranging from AU$1 to AU$3, according to analysts polled by CapitalIQ. Price (AUD): $1.26, Change: $-0.03, Percent Change: -2.3
Healius Could Solve Near-Term Gearing Issue With Imaging Sale -- Market Talk
0101 GMT - Healius could solve its near-term gearing challenges by selling its imaging business, Citi analyst Mathieu Chevrier writes in a note. A sale of the imaging business could be the most likely
Healius Begins Strategic Review of Assets, Structure Under New CEO
ustralian pathology and imaging provider Healius has begun a strategic review of its assets and structure that it said would be aimed at maximizing shareholder value.
Beaten-up ASX 200 Stock Jumps 14% on CEO Resignation
Healius Ltd (ASX: HLS) shares are storming higher on Tuesday morning.
Jarden Research Adjusts Healius' Price Target to AU$1.26 From AU$1.29, Keeps at Underweight
Healius (ASX:HLS) has an average rating of underperform and price targets ranging from AU$1 to AU$1.45, according to analysts polled by CapitalIQ. Price (AUD): $1.20, Change: $-0.07, Percent Change: -
Healius Needs Pathology to Step Up to Stay Within Covenants -- Market Talk
0021 GMT - Barrenjoey puts pathology-services provider Healius's gearing under the microscope following its 1H result. Barrenjoey now forecasts Ebitda of A$345.1 million in FY 2024, representing a 2%
Healius Downgraded to Sell From Neutral by Citi
Healius Downgraded to Sell From Neutral by Citi
Healius Target Price Cut 3.6% to A$1.35/Share by Macquarie>HLS.AU
Healius Target Price Cut 3.6% to A$1.35/Share by Macquarie>HLS.AU
Australian Shares Inch Up as Market Awaits Economic Data, US Fed Statements
Australian shares inched up on Tuesday as the market awaited the release of local and international economic data and statements from US Federal Reserve members. The S&P/ASX 200 Index rose 10.20 point
Healius Price Target Cut 4% to A$1.20/Share by Jefferies
Healius Price Target Cut 4% to A$1.20/Share by Jefferies
2 Popular ASX 200 Healthcare Shares Tanking on Earnings Updates
As earnings season rolls on, let's take a look at the reports for popular ASX 200 healthcare shares Polynovo Ltd (ASX: PNV) and Healius Ltd (ASX: HLS).
Healius 1H Net Loss A$635.8 Million
Healius 1H Net Loss A$635.8 Million
Healius Says Won't Pay an Interim Dividend
Healius Says Won't Pay an Interim Dividend
Healius Reports Wider H1 FY24 Loss as Revenue Slips 2%
05:21 PM EST, 02/26/2024 (MT Newswires) -- Healius Reports Wider H1 FY24 Loss as Revenue Slips 2% Price (AUD): $1.39, Change: $+0.01, Percent Change: +1.09%
Healius Price Target Cut 17% to A$1.37/Share by Morgans
Healius Price Target Cut 17% to A$1.37/Share by Morgans
Healius Target Price Cut 6.7% to A$1.40/Share by Macquarie>HLS.AU
Healius Target Price Cut 6.7% to A$1.40/Share by Macquarie>HLS.AU
Healius Says Impairment Tied to Near-Term Lower Volumes, Cash Flows
Healius Says Impairment Tied to Near-Term Lower Volumes, Cash Flows
Healius Taking New Steps to Restructure Pathology Business
Healius Taking New Steps to Restructure Pathology Business
Analysis
Price Target
No Data
